In a case that concluded just eight months after filing, Display Technologies, LLC and DexCom, Inc. jointly stipulated to dismiss with prejudice a patent infringement action centered on U.S. Patent No. 8,671,195 (‘US8671195B2′) in the Eastern District of Texas. Filed on December 12, 2023, and closed on August 15, 2024, the dispute targeted DexCom’s flagship G5, G6, and G7 Continuous Glucose Monitoring (CGM) systems — some of the most commercially significant wearable medical devices on the market. The court accepted the joint stipulation and ordered each party to bear its own costs and attorneys’ fees, a hallmark signal of a negotiated resolution.

This case carries meaningful implications for IP strategy across the medical device and digital health sectors. Patent assertion entities and practicing entities alike should note how rapidly the Eastern District of Texas can catalyze resolution of CGM-related infringement claims. R&D teams developing next-generation glucose monitoring or wearable biosensor technologies must account for the IP landscape staked out by assertion-focused plaintiffs, while in-house IP counsel at medtech companies should treat this case as a prompt to audit freedom-to-operate exposure across their connected device portfolios.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. 8,671,195 (Application No. 11/999,570) generally covers methods and systems for communicating and displaying data from remote or wearable sensor devices, including the transmission, processing, and presentation of real-time data streams to users or connected systems. In the context of this case, the asserted claims appear to relate to how CGM devices like DexCom’s G5, G6, and G7 transmit continuous physiological data — specifically glucose readings — to display or companion devices. The patent’s claims are relevant to the broader ecosystem of wireless, wearable health monitoring products that depend on real-time data communication architectures.

• • US8671195B2

Legal Representation

Plaintiff Counsel: Garteiser Honea PLLC (lead: Randall T. Garteiser)
Defendant Counsel: Fish & Richardson LLP (lead: Aaron P Pirouznia)

Litigation Timeline & Procedural History

The case was filed in the Eastern District of Texas, a jurisdiction renowned for its patent-plaintiff-friendly procedural environment, expedited docket management, and historically high rates of settlement prior to trial. Filing in this venue by a patent assertion entity like Display Technologies reflects a deliberate strategic choice, as the E.D. Texas consistently attracts high volumes of patent infringement actions involving consumer electronics and connected devices. The first-instance district court level means no appellate record was generated, and the court’s involvement was limited to case management through the stipulated dismissal.

At 247 days from filing to closure, this case moved at a pace consistent with pre-trial resolution — likely before claim construction or summary judgment briefing was completed. The dismissal with prejudice pursuant to a joint stipulation is the defining procedural hallmark: it bars Display Technologies from reasserting the same claims under US8671195B2 against DexCom in any future action. The order that each party bear its own costs and fees reinforces the inference of a negotiated license or covenant-not-to-sue arrangement, rather than a capitulation by either side. No damages were adjudicated, and no injunctive relief was issued by the court.

The Verdict & Legal Analysis

Outcome

The Eastern District of Texas accepted the parties’ Joint Stipulation of Dismissal and dismissed all claims and causes of action between Display Technologies, LLC and DexCom, Inc. with prejudice on August 15, 2024. No damages were awarded by the court, no injunctive relief was granted, and each party was ordered to bear its own costs, expenses, and attorneys’ fees. All pending motions and requests for relief not explicitly addressed were denied as moot, closing the case entirely without a merits adjudication.

Verdict Cause Analysis

The following legal grounds and procedural dynamics shaped the resolution of this infringement action:

• The asserted patent, US8671195B2, covers data communication and display technologies that Display Technologies alleged were infringed by DexCom’s G5, G6, and G7 CGM product lines, making the commercial scope of potential damages significant given DexCom’s market position.
• Dismissal with prejudice under a joint stipulation signals that the parties reached a private resolution — most likely a licensing agreement or covenant-not-to-sue — that rendered continued litigation unnecessary and foreclosed future re-assertion of the same patent claims.
• The mutual cost-bearing provision is a standard negotiated settlement term that avoids fee-shifting under 35 U.S.C. § 285 and suggests neither party sought to characterize the case as ‘exceptional’ or pursued a prevailing-party cost recovery.
• The Eastern District of Texas’s active case management and settlement pressure timelines likely accelerated the parties toward resolution before resource-intensive stages such as claim construction, expert discovery, or dispositive motion practice.

Legal Significance

1. 1. Because the dismissal was with prejudice and no claim construction order was issued, US8671195B2’s claim scope remains judicially unconstrued, leaving its meaning available for assertion — and potential challenge — in future litigation against other defendants in the CGM or connected health device space.
2. 2. The settlement-by-stipulation pattern in E.D. Texas CGM patent cases reinforces the venue’s role as a settlement-forcing mechanism, and practitioners should anticipate that similar assertion campaigns targeting wearable biosensor companies may follow a comparable accelerated resolution trajectory.
3. 3. No invalidity or non-infringement findings were made on the merits, meaning the patent retains its presumption of validity under 35 U.S.C. § 282, and third parties — including DexCom competitors — remain exposed to potential infringement claims under the same patent.

Strategic Takeaways

For Patent Attorneys:

• When defending CGM or wearable health device clients against patent assertion entities in E.D. Texas, pursue early claim construction analysis and invalidity contentions aggressively to build negotiating leverage before the plaintiff can anchor settlement expectations on trial threat alone.
• The mutual cost-bearing outcome signals that early settlement negotiations — rather than aggressive motion practice — may be the most cost-efficient path, but attorneys should confirm patent validity exposure via IPR or ex parte reexamination as a parallel track.
• Because US8671195B2 remains judicially unconstrued, any licensee of this patent or defendant in a related future action should seek claim construction rulings that narrow the patent’s scope, particularly with respect to data transmission and display claim elements.
• Garteiser Honea PLLC’s involvement as plaintiff’s counsel is a notable pattern indicator — tracking this firm’s other active dockets can help anticipate which other medical device or connected health companies may be targeted next under the same or related patents.

For IP Professionals:

• In-house IP teams at CGM and wearable device companies should immediately audit their product portfolios for exposure to US8671195B2 and related data communication patents held by Display Technologies, LLC, particularly as DexCom’s dismissal with prejudice does not protect third-party competitors.
• Monitor Display Technologies, LLC’s patent acquisition and litigation activity across PACER and USPTO assignment records — patent assertion entities frequently file sequential campaigns, and understanding their portfolio depth is critical for proactive licensing or design-around decisions.

For R&D Teams:

• Engineering teams developing next-generation CGM systems or wearable biosensors should conduct a freedom-to-operate review against US8671195B2’s claims, particularly regarding real-time data transmission protocols and display rendering architectures, before product launch.
• Consider design-around strategies that implement proprietary data communication stacks or display architectures that differentiate from the claim elements of US8671195B2, especially if your product roadmap involves connected glucose monitoring or continuous physiological sensing features.